Repatha Manufacturer Bridge Programs: How to Get Evolocumab Cheaper in 2026

Why Repatha Costs So Much, and Why Manufacturer Programs Matter

Repatha is a biologic PCSK9 inhibitor. Biologics require complex cell-culture manufacturing, which drives list prices that most patients cannot absorb without help.

The List Price Reality

The wholesale acquisition cost for evolocumab 140 mg every two weeks runs approximately $604, $612 per month as of early 2026. The annual list price therefore sits near $7,300. Few commercially insured patients pay that figure, but without a bridge program or copay card, specialty-tier cost-sharing can still reach $200, $600 per month depending on the plan design.

The FOURIER trial (N=27,564) established that evolocumab reduces LDL-C by a mean of 59% and cuts major adverse cardiovascular events (MACE) by 15% over a median follow-up of 2.2 years compared with placebo on top of statin therapy. (FOURIER, NEJM 2017) That level of LDL reduction is clinically meaningful for secondary prevention, which is why guideline bodies strongly support access. The American College of Cardiology / American Heart Association 2022 guideline on cholesterol management recommends PCSK9 inhibitor therapy for patients with established ASCVD whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe. (ACC/AHA 2022 Cholesterol Guideline, Circulation)

Why Prior Authorization Creates a Bridge Gap

Most insurers require prior authorization (PA) before covering Repatha. A PA review can take 3 to 15 business days, and 30 to 50% of initial requests are denied and require appeal. That gap between the prescribing visit and first fill is exactly what Amgen's bridge supply addresses.

Amgen SupportPlus: The Central Hub for All Repatha Assistance

Amgen runs every Repatha financial assistance program through a single platform called Amgen SupportPlus. One enrollment call or online form connects a patient to the copay card, bridge supply, patient assistance, and PA support services simultaneously.

How to Enroll

1. Call 1-844-REPATHA (1-844-737-2842), Monday through Friday 8 a.m. To 8 p.m. ET.
2. Complete the online form at repatha.com/savings with prescriber NPI, insurance information, and income documentation if applying for patient assistance.
3. A SupportPlus case manager confirms eligibility within one business day for the copay card, and within 3 to 5 business days for the full patient assistance program.

The prescriber's office can also initiate enrollment through the Amgen provider portal, which is the faster path when a PA is already in flight.

What SupportPlus Does Not Cover

Federal health care program beneficiaries (Medicare Part D, Medicaid, TRICARE) are not eligible for the commercial copay card under federal anti-kickback regulations. Separate pathways, the Amgen Patient Assistance Program and state pharmaceutical assistance programs, exist for that population. (Federal anti-kickback statute, 42 U.S.C. 1320a-7b)

The Repatha Copay Card (Commercial Insurance Patients)

The copay card is the highest-volume program Amgen runs for Repatha. For most commercially insured patients who clear the eligibility screen, it eliminates or nearly eliminates out-of-pocket cost.

Eligibility Criteria

• Must have commercial (private) insurance that covers Repatha.
• Must be a U.S. Resident.
• Must not be enrolled in any federal or state government insurance program as the primary payer.
• No income limit applies to copay card enrollment (income limits apply only to the patient assistance program).

Benefit Structure in 2026

The card covers the difference between what the plan pays and what Amgen sets as the patient's target out-of-pocket share, subject to a calendar-year maximum benefit. As of January 2026, that maximum is approximately $3,600 per year, which amounts to $300 per month. For most specialty-tier plans where cost-sharing runs $200, $400 per fill, the card effectively brings the monthly patient cost to $0.

The card is reloaded each January 1. Patients who exhaust the annual maximum before December may need to pay standard cost-sharing for the remaining months unless the patient assistance program bridges that gap.

Activation and Use

Once enrolled, the patient receives a copay card number (physical card or digital ID). The dispensing pharmacy, most fills go through specialty pharmacies such as Accredo, CVS Specialty, or AllianceRx Walgreens Prime, applies the card at point of sale. No paper claims are required from the patient.

The 30-Day Bridge Supply Program

The bridge supply program provides a free 30-day (one autoinjector pen or one SureClick device) while the insurance PA review is pending.

Clinical Rationale

Patients referred for Repatha typically have recent ASCVD events or markedly elevated LDL-C. A 2 to 4 week delay in starting a drug that reduces LDL-C by nearly 60% is not clinically trivial. The FDA's prescribing information for evolocumab notes the drug's rapid onset: LDL-C begins falling within days of the first injection, with near-maximal effect seen at two weeks. (Repatha prescribing information, FDA)

How to Request the Bridge Supply

The prescriber's office submits a bridge supply request through the Amgen SupportPlus provider portal, or a case manager initiates it during the enrollment call. Amgen ships directly to the patient's preferred address or to the specialty pharmacy. Turnaround is typically 2 to 3 business days after PA submission is confirmed.

The bridge supply is available once per patient per insurance episode. A patient who changes insurers and faces a new PA review may qualify for a second bridge supply.

Amgen Patient Assistance Program (Uninsured and Underinsured)

For patients with no insurance or whose insurance does not cover Repatha at all, the Amgen Patient Assistance Program (Amgen Assist 360) can provide evolocumab at no cost.

Income Eligibility

The program targets households at or below approximately 600% of the Federal Poverty Level (FPL). For a single-person household in 2026, 600% FPL is roughly $90,000 in annual gross income. For a family of four, that threshold is approximately $155,000. Income documentation, typically the most recent federal tax return or three months of pay stubs, is required.

What Patients Receive

Approved patients receive a 90-day supply of Repatha shipped directly from Amgen at no cost, renewed as long as eligibility persists and the prescriber reconfirms medical necessity annually. There is no per-refill paperwork for the patient once the initial enrollment is complete.

Processing Time

Expect 7 to 10 business days from complete application to first shipment. Incomplete applications, missing prescriber signature or income documentation, are the most common cause of delay.

Prior Authorization Support Through SupportPlus

Getting the PA approved is the single biggest determinant of long-term Repatha affordability. Amgen case managers can assist with PA submission, peer-to-peer review scheduling, and formal appeal letters.

What the PA Support Team Does

• Checks plan-specific coverage criteria before submission to avoid preventable denials.
• Prepares a clinical summary letter citing the patient's LDL-C value, statin history, and ASCVD risk category.
• Schedules a peer-to-peer call between the prescriber and the insurer's medical director when an initial denial is received.
• Drafts a formal appeal citing the ACC/AHA guideline recommendation and, where applicable, state external review rights.

Appeal Success Rates

Data from the American Heart Association suggest that up to 70% of initially denied PCSK9 inhibitor PAs are approved on appeal when a strong clinical record is presented. (AHA PCSK9 Access Statement, Circulation 2020) The SupportPlus PA team has access to Amgen's internal coverage database, which maps payer-specific clinical criteria updated monthly.

Medicare and Medicaid Patients: Separate Pathways

Federal program beneficiaries need a different approach entirely. The commercial copay card is off-limits, but several options remain.

Medicare Part D

Medicare Part D plans must cover at least one PCSK9 inhibitor in most formulary categories following CMS guidance. The Medicare Extra Help program (Low Income Subsidy) reduces Part D cost-sharing to nominal levels for qualifying patients. In 2026, the Inflation Reduction Act's $2,000 Part D out-of-pocket cap takes full effect, which materially reduces the annual exposure for Repatha patients on Medicare. (CMS IRA Part D changes, CMS.gov)

Medicaid

Medicaid coverage varies by state. Most states cover PCSK9 inhibitors for familial hypercholesterolemia (FH) with prior authorization, citing NHLBI FH guidelines. Patients on Medicaid who face PA denials should ask their prescriber to submit documentation of confirmed FH using Simon Broome or Dutch Lipid Clinic Network criteria. (NHLBI FH Expert Panel Report)

State Pharmaceutical Assistance Programs

Over 30 states operate pharmaceutical assistance programs (SPAPs) that supplement Medicare Part D cost-sharing. The National Council on Aging maintains a BenefitsCheckUp database where patients can identify state-specific programs. Contact details vary; SupportPlus case managers can help identify applicable programs.

Independent Copay Assistance Foundations

When the Amgen copay card benefit is exhausted before year-end, independent foundations may cover the remaining cost-sharing gap.

HealthWell Foundation

HealthWell Foundation operates a cardiovascular disease fund that covers cost-sharing for PCSK9 inhibitors for commercially insured patients who meet income criteria (generally at or below 500% FPL). Benefit amounts and fund availability change quarterly. (HealthWell Foundation eligibility portal)

Patient Advocate Foundation Co-Pay Relief

The Patient Advocate Foundation Co-Pay Relief program offers assistance across multiple disease categories. The cardiovascular fund has covered evolocumab cost-sharing for patients with FH and established ASCVD in prior years. Fund opening dates are announced on the foundation's website. (Patient Advocate Foundation)

Both foundations operate independently of Amgen. Medicare patients are eligible for foundation assistance, unlike the manufacturer copay card.

Pharmacy-Level Discounts and GoodRx

GoodRx and similar discount card platforms do offer coupons for Repatha, but the savings are modest relative to the list price because evolocumab is a biologic with limited generic competition. As of early 2026, GoodRx prices for a 30-day supply (two 140 mg autoinjectors) cluster around $520, $560 depending on pharmacy.

For patients with commercial insurance, the Amgen copay card almost always delivers a better result than GoodRx. GoodRx becomes relevant only for patients who are ineligible for the copay card and do not yet qualify for the patient assistance program, or for patients in the brief window between insurance plans.

Using a discount card like GoodRx typically means paying cash and not applying the cost toward the insurance deductible. Patients approaching their annual deductible should weigh that trade-off before opting for the discount card route.

Switching to Every-Four-Week Dosing to Reduce Fill Frequency

Evolocumab is FDA-approved at two dosing schedules: 140 mg every two weeks or 420 mg once monthly. The FOURIER trial used both regimens and found equivalent LDL-C reduction between them. (FOURIER dosing equivalence, NEJM 2017) The 420 mg monthly dose requires a single 3.5 mL prefilled cartridge injected via the SureClick autoinjector in one sitting.

From an access standpoint, monthly dosing means one fill per month instead of two, which can simplify specialty pharmacy logistics and, in some PA structures, reduces the number of authorization touchpoints per year. It does not change the drug cost per month at list price, but it may reduce specialty pharmacy dispensing fees for patients paying partially out of pocket.

The HealthRX Decision Framework: Matching Patients to the Right Program

The right cost-reduction pathway depends on four variables: insurance type, income, LDL-C urgency, and whether a PA has been submitted. Use the following logic in sequence.

Step 1. Confirm insurance type. Commercial insurance: proceed to copay card enrollment through SupportPlus simultaneously with PA submission. Request bridge supply on the same call. Medicare/Medicaid: skip the copay card. Proceed to Extra Help screening (Medicare) or Medicaid PA with FH documentation.

Step 2. Assess urgency. Recent ACS or stroke within 90 days: request bridge supply immediately. Do not wait for PA approval to initiate treatment. The bridge supply ships in 2 to 3 business days.

Step 3. Check income. If uninsured or underinsured and household income is at or below 600% FPL: apply for the Amgen Patient Assistance Program concurrently with any PA.

Step 4. Plan for year-end depletion. Enroll in a HealthWell or Patient Advocate Foundation fund in Q3 if the copay card benefit is tracking toward exhaustion. Fund applications typically take 3 to 5 business days.

Step 5. Document the PA trail. Keep copies of every PA submission, denial letter, and peer-to-peer call date. State external review rights (available in all 50 states for medically necessary treatments denied by commercial insurers) require a documented appeal record under the ACA. (ACA external review rights, HHS)

What Clinicians Should Tell Patients at the Prescribing Visit

Prescribers who hand patients a Repatha prescription without a financial navigation plan are setting up a 30 to 50% abandonment rate at the pharmacy counter. Three actions at the prescribing visit reduce that rate substantially.

First, submit the PA from the office, not from the pharmacy. PA submissions originating in the prescribing office are processed faster and have better documentation. Second, call SupportPlus (1-844-REPATHA) from the exam room or direct the medical assistant to initiate enrollment before the patient leaves. Third, confirm the patient's insurance type so the correct program is activated. Sending a Medicare patient home with a commercial copay card enrollment form wastes a week.

The ACC/AHA 2022 guideline specifically states: "Clinicians should be aware of and utilize manufacturer patient support programs and independent foundation copay assistance to reduce barriers to PCSK9 inhibitor initiation." (ACC/AHA 2022 Cholesterol Guideline, Circulation)

Real-World LDL-C Outcomes at Stake

Access delays have measurable clinical consequences. A 2022 analysis published in JAMA Cardiology examined 6,015 patients with established ASCVD who were prescribed PCSK9 inhibitors; 38% never filled the first prescription, largely due to cost and PA delays. Among those who did fill, mean LDL-C fell from 103 mg/dL to 42 mg/dL at 12 months. (JAMA Cardiology 2022 PCSK9 real-world adherence) That 61 mg/dL reduction translates, using Mendelian randomization data, to an estimated 20 to 25% reduction in lifetime MACE risk for each mmol/L of sustained LDL-C lowering. (Ference et al., JAMA 2019)

The financial assistance programs described above are not administrative conveniences. They are the mechanism by which guideline-recommended therapy actually reaches patients.